MPM BioImpact LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001687078

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q3 2025 · 40 positions · Total reported value $610.88M · Top-10 concentration 48.8% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 81.2% · 7 new · 21 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +31.4% · vs SPY +16.6% · Prev Value $1.29B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2025 13F filing, MPM BioImpact LLC disclosed 40 equity positions with a combined reported value of $610.88M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 48.8% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were MDGL ($46.06M), CGEM ($45.35M), RNAM ($33.11M). By sector, the heaviest allocations are Health Care 92.7%, Other 7.3%. Versus the prior quarter, allocation shifted toward Other (+0.5pp).

Versus the prior quarter, MPM BioImpact LLC opened 7 new positions, trimmed 21 and fully exited 11, a turnover rate of 81.2% of positions. The portfolio's overlap with the prior quarter was 65% of names.

The largest new positions opened in Q3 2025 were SNDX ($21.16M), LQDA ($4.55M), PVLA ($4.23M).

Of the 11 positions fully exited versus the prior quarter, the largest were GH ($23.04M), MLTX ($14.80M), MBX ($14.77M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • SNDX SYNDAX PHARMACEUTICALS INC · $21.16M
  • LQDA LIQUIDIA CORPORATION · $4.55M
  • PVLA PALVELLA THERAPEUTICS INC NEW COM · $4.23M
  • ENGN ENGENE THERAPEUTICS INC · $3.62M
  • URGN UROGEN PHARMA LTD COM · $2.69M
  • RAPP RAPPORT THERAPEUTICS INC · $2.13M
  • ASMB ASSEMBLY BIOSCIENCES INC · $1.02M

Fully Exited (vs previous quarter)

  • GH GUARDANT HEALTH INC · prev qtr: $23.04M
  • MLTX MOONLAKE IMMUNOTHERAPEUTICS · prev qtr: $14.80M · history
  • MBX MBX BIOSCIENCES INC COM · prev qtr: $14.77M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $12.34M
  • OLMA OLEMA PHARMACEUTICALS INC · prev qtr: $10.13M
  • REPL REPLIMUNE GROUP INC · prev qtr: $9.14M
  • NUVB NUVATION BIO INC · prev qtr: $9.01M
  • TSHA TAYSHA GENE THERAPIES INC · prev qtr: $6.82M · history

Insider Transactions (Form 4)

Latest MPM BioImpact LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

MPM BioImpact LLC, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 37 positions worth $1.64B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-106989 (status: Approved), registered 2016-01-04
  • Regulatory AUM (Form ADV): $3.56B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 14 private funds, of which 3 hedge funds

Portfolio Structure

  • 37 positions · $1.64B reported value (Q2 2026)
  • Top 10 holdings = 55.3% of reported value
  • Largest position: CGEM (CULLINAN THERAPEUTICS INC) at 10.8%
  • Average position size: $44.32M

Sector Tilt

  • Health Care 98.7%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 7 new, 7 added, 21 reduced, 11 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 92.7%
Other 7.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 100.42K $46.06M 7.54%
7.54%
Hold
2 7.65M $45.35M 7.42%
7.42%
Hold
3 760.02K $33.11M 5.42%
5.42%
Hold
4 3.41M $31.17M 5.10%
5.10%
Hold
5 1.72M $27.91M 4.57%
4.57%
Hold
6 438.48K $26.91M 4.41%
4.41%
Hold
7 745.06K $25.25M 4.13%
4.13%
Hold
8 1.38M $21.16M 3.46%
3.46%
New
9 1.73M $20.75M 3.40%
3.40%
Hold
10 341.50K $20.30M 3.32%
3.32%
Hold
11 503.40K $20.21M 3.31%
3.31%
Add
12 789.70K $18.56M 3.04%
3.04%
Hold
13 1.45M $18.30M 3.00%
3.00%
Hold
14 5.08M $17.77M 2.91%
2.91%
Reduce
15 549.26K $16.48M 2.70%
2.70%
Hold
16 563.08K $16.36M 2.68%
2.68%
Hold
17 98.92K $15.92M 2.61%
2.61%
Hold
18 614.28K $15.01M 2.46%
2.46%
Hold
19 315.72K $14.74M 2.41%
2.41%
Hold
20 14.71M $14.25M 2.33%
2.33%
Hold
21 700.00K $13.49M 2.21%
2.21%
Add
22 1.30M $13.10M 2.14%
2.14%
Hold
23 3.90M $12.73M 2.08%
2.08%
Hold
24 2.28M $11.92M 1.95%
1.95%
Hold
25 395.70K $11.90M 1.95%
1.95%
Hold
26 1.51M $11.02M 1.80%
1.80%
Hold
27 1.05M $10.55M 1.73%
1.73%
Hold
28 150.00K $10.14M 1.66%
1.66%
Add
29 1.63M $10.09M 1.65%
1.65%
Hold
30 2.89M $7.89M 1.29%
1.29%
Hold
31 2.41M $4.75M 0.78%
0.78%
Hold
32 200.00K $4.55M 0.74%
0.74%
New
33 67.42K $4.23M 0.69%
0.69%
New
34 555.19K $4.18M 0.68%
0.68%
Hold
35 380.00K $3.88M 0.64%
0.64%
Reduce
36 530.30K $3.62M 0.59%
0.59%
New
37 135.00K $2.69M 0.44%
0.44%
New
38 71.81K $2.13M 0.35%
0.35%
New
39 819.92K $1.44M 0.24%
0.24%
Hold
40 39.66K $1.02M 0.17%
0.17%
New

FAQ

What did MPM BioImpact LLC buy in 2025-Q3?

In its 2025-Q3 13F filing, MPM BioImpact LLC reported 40 equity positions worth $610.88M in aggregate; its largest disclosed positions were MDGL ($46.06M), CGEM ($45.35M), RNAM ($33.11M).

How large is MPM BioImpact LLC's portfolio?

MPM BioImpact LLC reported $610.88M of long equity holdings across 40 positions as of 2025-Q3. Top-10 holdings account for 48.8% of reported value.

What is MPM BioImpact LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/mpm-bioimpact/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →